Evidence map›Paper›PMID 40457498›Full record

ArticleStem cell research & therapy2025

Engineering a controlled cardiac multilineage co-differentiation process using statistical design of experiments.

Hirokazu Akiyama, Yosuke Katayama, Kazunori Shimizu, Hiroyuki Honda

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hirokazu AkiyamaDepartment of Biomolecular Engineering, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603, Japan. akiyama.hirokazu.j2@f.mail.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0002-8217-341X
Yosuke KatayamaDepartment of Biomolecular Engineering, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603, Japan.
Kazunori ShimizuDepartment of Biomolecular Engineering, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603, Japan.ORCID http://orcid.org/0000-0002-9713-7016
Hiroyuki HondaDepartment of Biomolecular Engineering, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603, Japan. honda@chembio.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0002-7411-812X

Funding

Chubei Itoh Foundation Chubei Itoh FoundationJapan Society for the Promotion of Science 23K04505Naito Science and Engineering Foundation Naito Science and Engineering FoundationTokai Industrial Technology Foundation Tokai Industrial Technology Foundation
6 · The paper itself

Abstract

backgroundThe heart is a complex organ composed of diverse cell types, whose interplay is crucial for development, tissue homeostasis, and disease progression. A potential approach to recapitulate this heterotypic multicellular environment is the co-differentiation of induced pluripotent stem cells (iPSCs) into multiple cardiac cell types, facilitating the unlocking of their full potential for regenerative medicine and drug development. However, the inherent complexity of co-differentiation, where multiple differentiation factors simultaneously influence the induction of multiple cell types, presents a significant challenge in achieving high controllability over the process toward the desired outcome. Thus, a robust strategy is essential for engineering a controlled co-differentiation process with broader applicability.

methodsGiven the importance of heterotypic cellular proportions in facilitating proper interactions, we present a new strategy to engineer a controlled cardiac co-differentiation process from iPSCs using statistical design of experiments to simultaneously generate cardiomyocytes, mural cells, and endothelial cells, which are major constituents of the heart.

resultsWe divided the process into two stages: progenitor cell induction and the subsequent trilineage co-differentiation, allowing for stage-specific optimization. Given that the performance of progenitor cell induction may critically influence the overall process performance, we carefully optimized activin A and CHIR-99021 using the sequential design of experiments to achieve approximately 95% induction efficiency of KDR+/PDGFR-α+ cardiogenic mesoderm cells from iPSCs with minimal batch-to-batch variability. In the trilineage co-differentiation stage, we developed unique multi-response models to delineate trilineage co-differentiation ratios within a defined parameter space of WNT signal inhibitor and vascular endothelial growth factor. This enabled the identification of potential conditions that steer co-differentiation toward desired cellular constitutions, a critical factor of effective cellular interplays. Repeated trilineage co-differentiation experiments confirmed the high process controllability, with a close match between actual and predicted differentiation ratios. Furthermore, cardiomyocytes from trilineage co-differentiation exhibited a more mature sarcomere gene expression profile than those from monolineage differentiation.

conclusionsThese results highlight the effectiveness of our strategy for engineering a stem cell co-differentiation process and its applicability where multicellular interactions are crucial.

Indexed as

Cell DifferentiationInduced Pluripotent Stem CellsMyocytes, CardiacAnimalsCell LineageEndothelial CellsHumansCardiac co-differentiationDesign of experimentsMulti-response modelingPluripotent stem cellsProcess engineering

Identifiers

PMID40457498
PMCPMC12131582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.